HeartBeam (NASDAQ: BEAT) Is ‘One to Watch’

✎ Contributed by Ty Griffin

HeartBeam has developed the first cable-free system capable of synthesizing a 12-lead ECG from 3D, non-coplanar electrical signals captured in real time.
Patients can have the HeartBeam System with them at all times, ready to record an ECG in 30 seconds at home or anywhere when they feel symptoms to reduce delays in care.
The HeartBeam System is now FDA cleared for arrhythmia assessment, with additional FDA review underway for its 12-lead ECG synthesis software for the same indication.
A recent partnership with AccurKardia enhances HeartBeam’s arrhythmia solution with an FDA-cleared automated rhythm interpretation software.
HeartBeam holds 20 issued patents, with additional allowed and pending applications, protecting its proprietary hardware, software, and algorithmic capabilities.
Commercial launch is expected to be imminent, targeting a $500 million concierge SAM and broader multibillion-dollar patient pay market, supported by a high-margin, recurring revenue model.

HeartBeam (NASDAQ: BEAT) is a medical technology company developing a groundbreaking solution for at-home detection and monitoring of cardiac conditions. The company is creating the first ever cable-free synthesized 12-lead ECG platform designed to give patients the ability to record their symptoms the moment they occur, wherever they are. By providing synthesized, 12-lead ECG data, physicians can quickly assess the symptoms and ensure patients get the care they need in a timely manner. It also eliminates the need for wires, complex setup, or clinical staff, thus allowing synthesized 12-lead ECG signals to be accessible outside of a medical setting.

HeartBeam’s vision is to redefine cardiac care by enabling early detection, proactive monitoring, and informed clinical decisions outside the confines of a traditional medical setting. Its patented approach not only delivers similar, but not identical, accuracy of conventional 12-lead ECGs for arrhythmia detection…